Genetic association studies have identified 215 risk loci for inflammatory bowel disease 1-8 , thereby uncovering fundamental aspects of its molecular biology. We performed a genome-wide association study of 25,305 individuals and conducted a meta-analysis with published summary statistics, yielding a total sample size of 59,957 subjects. We identified 25 new susceptibility loci, 3 of which contain integrin genes that encode proteins in pathways that have been identified as important therapeutic targets in inflammatory bowel disease. The associated variants are correlated with expression changes in response to immune stimulus at two of these genes (ITGA4 and ITGB8) and at previously implicated loci (ITGAL and ICAM1). In all four cases, the expression-increasing allele also increases disease risk. We also identified likely causal missense variants in a gene implicated in primary immune deficiency, PLCG2, and a negative regulator of inflammation, SLAMF8. Our results demonstrate that new associations at common variants continue to identify genes relevant to therapeutic target identification and prioritization.
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Inflammatory bowel disease (IBD) is a chronic, debilitating disorder of the gastrointestinal tract that includes two common disease subtypes, Crohn's disease and ulcerative colitis. Disease pathogenesis is poorly understood but is likely driven by a dysregulated immune response to unknown environmental triggers in genetically susceptible individuals. Treatment regimes often use potent immunomodulators to achieve and maintain remission of symptoms. However, patients commonly experience side effects, lose response to treatment or develop complications of IBD, with many ultimately requiring major abdominal surgery. Previous genome-wide association studies (GWAS) and targeted follow-up using the Immunochip have been very successful at identifying genetic risk loci for IBD, but the increased biological understanding has not yet had a substantial impact on therapy for these disorders.
To further expand understanding of the biology of these disorders, we carried out a GWAS of 12,160 IBD cases and 13,145 population controls of European ancestry who had not been included in any genome-wide meta-analysis of IBD thus far (Online Methods and Supplementary Table 1 ). We imputed genotypes using a reference panel comprising whole-genome sequences from 4,686 IBD cases 9 and 6,285 publically available population controls 10, 11 . Following quality control (Online Methods), we tested 9.7 million sites for association. At the 232 IBD-associated SNPs in the latest meta-analysis by the International IBD Genetics Consortium 1 , 228 had effects in the same direction in our data, 188 showed at least nominal evidence of replication (P < 0.05) and none showed significant evidence of Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease heterogeneity of effect by Cochrane's Q test. Among the replicated loci was a genome-wide significant association at 10q25 that was only significantly associated previously with Crohn's disease in individuals of East Asian ancestry 3, 7 , further supporting the notion of almost complete sharing of genetic risk loci across populations 1 . We performed meta-analysis of our new GWAS data with previously published summary statistics from 12,882 IBD cases and 21,770 population controls imputed using the 1000 Genomes Project reference panel 1 (Supplementary Figs. 1-3 and Supplementary Table 2 ). We observed inflation of the summary statistics (λ GC = 1.23 and 1.29 for Crohn's disease and ulcerative colitis, respectively), but LD score regression demonstrated that this inflation was due to broad polygenic signal rather than confounding population substructure (both intercepts = 1.09; Online Methods).
We identified 25 new loci at genome-wide significance ( Table 1) . To identify causal variants, genes and mechanisms, we performed a summary statistic fine-mapping analysis on these loci, as well as 40 previously discovered loci that were genome-wide significant in our data but where fine-mapping had not yet been attempted 12 (Online Methods and Supplementary Table 3 ). To be confident about our fine-mapping inferences, we restricted subsequent analyses to 12 signals where we had high-quality imputed data for all relevant variants (Online Methods). At 6 of these 12 loci, we identified a single variant with >50% probability of being causal ( Table 2 and Supplementary  Figs. 4-6 ). Among these loci were two where a single variant had >99% probability of being causal, including a missense variant predicted to affect protein function in SLAMF8 (rs34687326, p.Gly99Ser; Fig. 1a ) and an intronic variant in the key regulator of T helper type 17 (T H 17) cell differentiation RORC 13 . SLAMF8 is a cell surface receptor that is expressed on activated myeloid cells and has been reported to negatively regulate inflammatory responses by inhibiting the migration of these cells to sites of inflammation 14 and repressing their production of reactive oxygen species (ROS) 15 . This, together with the observation that the risk-decreasing allele of rs34687326 (minor allele frequency (MAF) = 0.1) is predicted to affect protein function (CADD = 32.0, 92nd percentile of missense variants) 16 , suggests that further experiments evaluating a possible gain-of-function mechanism may be worthwhile. RORC encodes RORγt, the master transcriptional regulator of T H 17 cells 13 and group 3 innate lymphoid cells 17 . Both of these cell types have important roles in defense at mucosal surfaces, especially in the intestine, and have been shown to contribute to the homeostasis between the intestinal immune system and gut microbiota 18, 19 , an equilibrium that is known to be lost in IBD 20 . Pharmacological inhibition of RORγt has been shown to offer therapeutic benefit in mouse models of intestinal inflammation and reduces the proportional number of T H 17 cells isolated from the primary intestinal samples of human patients with IBD 21 .
In loci where fine-mapping was less clearly resolved, we searched for likely functional variants, observing a missense variant (CADD = 16.5, 50.2% probability of causality) in PLCG2. Furthermore, after conditioning on this variant, we discovered a second, independent likely functional (CADD = 34.0, 74.6% probability of causality) missense variant in the same gene (P = 2 × 10 −8 ). PLCG2 encodes a phospholipase enzyme that has a critical role in regulating immune pathway signaling 22 and has previously been implicated in two autosomal dominant immune disorders. Intragenic deletions mapping to the autoinhibitory domain of the encoded protein cause antibody deficiency and immune dysregulation (familial cold autoinflammatory syndrome 3; MIM 614468) 23 , and heterozygous missense variants (for example, p.Ser707Tyr) lead to a phenotype that includes intestinal inflammation 24 (Fig. 1b) .
A more general overlap between candidate IBD GWAS genes and genes implicated in Mendelian disorders of inflammation and immunity was previously observed for 163 loci discovered at that time 25 . l e t t e r s l e t t e r s
We replicated this finding in our list of 241 loci (P < 1 × 10 −6 ; Supplementary Table 4 ) and observed that this enrichment was even stronger when considering just the 26 loci where a gene could be confidently implicated by fine-mapping to a coding variant or colocalization with an expression quantitative trait locus (eQTL; 27% versus 3% enrichment, P = 2 × 10 −5 ). In addition to PLCG2, we identified an association between Crohn's disease and an intronic variant in NCF4 (P = 1.76 × 10 −8 ). This gene encodes p40 phox , a component of the nnicotinamide adenine dinucleotide phosphate (NADPH) oxidase system that is responsible for the oxidative burst in innate immune cells, which is a key mechanism for killing phagocytosed bacteria. Rare pathogenic variants in NCF4 cause autosomal recessive chronic granulomatous disease, characterized by Crohn's disease-like intestinal inflammation and defective ROS production in neutrophils 26 . Our associated variant, rs4821544, had previously been suggestively associated with small bowel Crohn's disease 27, 28 , and when we stratified patients by disease location we found that the effect was consistently stronger for small bowel disease than for large bowel disease (Supplementary Fig. 7) . Among the remaining 21 newly identified loci, we noted 3 that were within 150 kb of integrin genes (ITGA4, ITGAV and ITGB8), while a previously associated locus overlapped with a fourth integrin gene, ITGAL. Furthermore, a recent study demonstrated that there is an IBD-specific association that affects expression of ICAM1, which encodes the binding partner of the ITGAL gene product 29 . Integrins are cell adhesion mediators with bidirectional signaling capabilities that have a crucial role in leukocyte homing and cell differentiation in inflammation and cancer 30 . Given the strong candidacy of these genes, we sought potentially causal molecular mechanisms that would connect the IBD-associated SNPs with integrin regulation. Our finemapping analysis excluded the possibility that these associations are caused by protein-coding changes, so we next tested for effects of IBD risk SNPs on integrin gene expression in immune cells using 12 publicly available eQTL data sets. As many eQTLs and GWAS signals show some degree of correlation, inferences about causality require more robust statistical colocalization of the two signals. Remarkably, we observed that three of our five associations had >90% probability of being driven by the same variants as monocyte-specific stimulus response eQTLs (ITGA4, P LPS 24 h = 0.984; ITGAL, P LPS 24 h = 0.980; ICAM1, P LPS 2 h = 0.961 (where P LPS is the probability of colocalization between our GWAS signal and the eQTL due to response to lipopolysaccharide); Supplementary Table 5 ). A fourth association, at ITGB8, was difficult to map owing to extended linkage disequilibrium (LD) in the locus but showed intermediate evidence of colocalization (P LPS 24 h = 0.712) in response to the same stimulus (Fig. 2) . All four of the alleles increasing IBD risk upregulate expression of their respective genes, suggesting that increased levels of proinflammatory cell surface markers in response to stimulus may be a consistent mechanism of action. Proving this hypothesis would require showing that IBD risk alleles causally change stimulus response expression (for Gene body diagrams and protein domain annotations were taken from Ensembl, and partial predicted crystal structures for both proteins were obtained from the SWISS-MODEL repository. l e t t e r s example, in studies with targeted editing of each allele in cell lines homozygous for the low-risk haplotype) and, moreover, that such changes have physiological relevance to disease processes. One line of evidence that supports such disease relevance for integrins and their counter-receptors is the recent emergence of these molecules as important therapeutic targets in IBD. Most promisingly, the monoclonal antibodies vedolizumab and etrolizumab, which target the components of the α4β7 dimer (encoded by ITGA4 and ITGB7, respectively, and responsible for the gut homing specificity of certain leukocytes), have demonstrated efficacy in IBD [31] [32] [33] . Additionally, an antisense oligonucleotide targeting ICAM1 has shown promise in the treatment of ulcerative colitis and pouchitis 34 . The importance of gut selectivity for therapeutic approaches is highlighted by the antibodies that bind the αL and α4 integrin subunits (encoded by ITGAL and ITGA4, respectively). Therapies targeting αL (efalizumab) and α4 (natalizumab) demonstrated potential in Crohn's disease 35, 36 , but both medications have been associated with progressive multifocal leukoencephalopathy (PML) 37 . This potentially fatal condition is likely mediated by binding of the antibodies to integrin dimers that are not specific to the gut, leading to impaired leukocyte migration to the central nervous system and JC virus infection of the brain. Because of the risk of PML, efalizumab has been withdrawn from the market and natalizumab is not licensed for Crohn's disease in Europe.
Integrins are not only important in cell trafficking but can also participate in cellular signaling. For example, the αVβ8 heterodimerboth subunits of which are encoded by genes that are now within confirmed IBD loci (ITGAV and ITGB8, respectively)-is a potent activator of transforming growth factor (TGF)-β (ref. 38) , with a range of cell-type-specific effects. Furthermore, mice with dendritic cell-specific deletion of this complex have impaired regulatory T cell function and severe colitis 39 , whereas deleting the complex in regulatory T cells themselves prevents these cells from suppressing l e t t e r s pathogenic T cell responses during active inflammation 40 . Although no current IBD therapeutics target αVβ8 directly, promising early results for an oral antisense oligonucleotide to the inhibitory TGF-β signaling component SMAD7 (ref. 41) , itself encoded by a locus identified by genetic association studies for IBD 25 , demonstrate the therapeutic potential of modifying TGF-β signaling in Crohn's disease. In addition to supporting the connections with anti-integrin and anti-TGF-β therapies described above, IBD GWAS have previously implicated loci containing other therapeutically relevant genes, such as those in signaling pathways relevant to the targets of anti-TNF and anti-p40 IBD therapies ( Fig. 3 and Supplementary Table 6 ). These discoveries have demonstrated that the effect sizes of GWAS associations do not necessarily reflect the importance or therapeutic relevance of their underlying biological pathways. For example, the modest odds ratios for the signals near integrin genes (1.10-1.12) required tens of thousands of samples to be detected at genome-wide significance. Furthermore, analyses aimed at understanding the specific cellular contexts in which these genes are active in IBD, as well as the risk-increasing direction of effect (for example, consistent upregulation of integrins in response to LPS stimulus), are only beginning to bear fruit.
Our study has demonstrated that continuing to pursue GWAS, even in a well-studied complex disease like IBD, has the potential to complement other powerful approaches, such as targeted genotyping (via the Immunochip) and large-scale genome and exome sequencing. In two cases, we have implicated genes in which different variants have previously been shown to cause immune-related Mendelian disorders, echoing a connection made to the very first Crohn's disease risk gene, NOD2, in which rare missense mutations cause the autosomal dominant granulomatous disorder Blau syndrome 42 . Finally, although the individual effect sizes of our newly discovered associations are modest, our results show that GWAS analysis continues to discover new susceptibility loci, thereby helping to enhance understanding of many aspects of disease biology, including possible mechanisms for known therapies. For example, four IBD associations that plausibly colocalize with variants linked to changes in integrin expression underscore the value of comprehensive catalogs of the regulatory consequences of GWAS variants in specific cells and contexts. Even when specific genes are implicated, cellular assays with relevance to disease physiology (for example, evaluating protein response to bacterial stimulus in colonic organoids) will be needed to achieve the ultimate payoff from prospectively mining these signals for promising targets for new therapeutics.
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Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper. Figure 3 IBD-associated loci containing genes in immune pathways related to classes of approved therapeutics. All IBD susceptibility loci were divided into the studies where they were first identified 1 . Loci that contain a gene in one of four signaling pathways related to targets of three classes of approved IBD therapeutics (Online Methods) are highlighted, with those where the pathway gene has been confidently identified as the causal IBD gene labeled. Despite the general pattern of decrease in effect size from left to right, therapeutically relevant associations continue to be found for loci with lower effect sizes.
